To translate data from cellular models to HCC patients, we determined serum levels of bFGF in treatment naïve patients, in patients exclusively treated first-line with Sora and in patients treated first-line with Sora and second-line with Rego (Table S1). This evidence concerns the gene FGF2 and hepatocellular carcinoma.